Roche decries biotech's 'bubble'; AbbVie presses into Phase III with uterine fibroid drug;

@FierceBiotech: Adding iridium may offer a new approach to antibiotic resistance. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Building its cardio drug portfolio, Amgen bags Dezima in $1.55B deal. News | Follow @JohnCFierce

@DamianFierce: "Ubiquitin" sounds like a McGuffin from a bad sci-fi movie and also it's the target of a new $150M $CELG partnership. Release | Follow @DamianFierce

> Roche ($RHHBY) CEO Severin Schwann reiterated his concerns that biotech is in the midst of a "bubble," saying valuations of small drugmakers have become prohibitively high. News

> AbbVie ($ABBV) and partner Neurocrine Biosciences ($NBIX) are planning to launch a Phase III trial of their uterine fibroid treatment elagolix in early 2016 after tracking a positive effect in Phase IIb. More

> Amid rampant M&A in biopharma, diabetes magnate Novo Nordisk ($NVO) has largely shied away from big deals, part of CEO Lars Sørensen's ethos of focusing on organic growth. Story

Medical Device News

@FierceMedDev: MDxHealth's $8.8M acquisition of NovioGendix is a liquid biopsy play. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: FDA begs manufacturers to participate in global single audit pilot, says next stage may not be voluntary. ICYMI | Follow @VarunSaxena2

@EmilyWFierce: Germany's ERBA Diagnostics grabs Lumora for molecular Dx tech. FierceDiagnostics story | Follow @EmilyWFierce

> Pentax backs $8M+ round for electrosurgery startup Creo. More

> Illumina, Sloan Kettering partner to develop circulating tumor DNA diagnostics. Article

Pharma News

@FiercePharma: Report: Cancer drug spending fuels large increases in Medicare discount drug program. More | Follow @FiercePharma

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. More | Follow @CarlyHFierce

> Will payers make SGLT2 moves on Jardiance CV data? Not just yet. More

> Analysis: New Novartis heart failure med has consumers talking. Item

> Report: Cancer drug spending fuels large increases in Medicare discount drug program. Article

Biotech Research News

> Controversial resveratrol triggers new headlines--this time for Alzheimer's. Story

> Stanford team spotlights a new target for childhood brain tumors. Report

> Adding iridium may offer a new approach to antibiotic resistance. Story

> Caltech IDs an antibody that can thwart HIV. Item

> U.K. investigators say diabetes drug may target pancreatic cancer stem cells. Article

Diagnostics News

> Agilent buys Seahorse Bio for $235M to increase presence in research labs. More

> MDxHealth's $8.8M acquisition of NovioGendix is a liquid biopsy play. News

> Exosome Diagnostics reveals positive data for lung cancer liquid biopsy test. Story

> Foundation Medicine unveils new NGS cancer tool amid sluggish reimbursement. Article

> Pathway Genomics launches liquid biopsy test for early cancer screening. Report

Pharma Marketing News

> GSK settles big media review, chooses incumbents for estimated $900M account. Report

> Gallup charts another big slide for pharma's public image. Story

> Faster track to 'megablockbuster'? Novartis' Entresto already soaring on social media. Article

> Obama taps former Duke researcher to lead FDA. Item

> How much is first-to-market worth? There's a formula for that. More

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.